New Chief Medical Officer for BTG
Prof Steven Myint appointed as company’s first CMO
London, UK, 19th February 2007: BTG plc (LSE: BGC), the medical innovations company, announces that it has appointed Prof Steven Myint as Chief Medical Officer.
Prof Myint has most recently served as Dean of Medicine and Professor of Medicine and Microbiology at the University of Surrey, UK. From 2003-2005 he was Group Medical Director, Oncology/Biologicals at GlaxoSmithKline, and prior to that held a number of senior medical roles in GlaxoSmithKline and SmithKline Beecham Pharmaceuticals with responsibility for therapeutic areas including oncology, psychiatry/neurosciences and biological medicines He is a member of a number of medical advisory bodies and government and international committees.
Louise Makin, BTG’s Chief Executive Officer commented: “We are extremely pleased that Steve has joined the Company. He brings tremendous industry experience, medical knowledge and leadership that will help us as we continue to expand and develop our pipeline of pharmaceutical programmes.”
For further information contact
Andy Burrows, Director of Investor Relations
+44 (0)20 7575 1741; mobile: +44 (0)7990 530605
De Facto Communications
Maria Patey/Richard Anderson
+44 (0)20 7861 3838
BTG in-licenses, develops and commercialises pharmaceuticals and other medical technologies. With a substantial and growing revenue stream of royalties and milestone payments from out-licensed products, BTG continues to strengthen its pipeline of preclinical and clinical development programmes. Active in the fields of oncology, diseases of ageing, neuroscience, drug repositioning and medical devices, BTG works from its offices in London, Philadelphia and Osaka with a global partner network of healthcare companies and research organisations. For further information, visit: www.btgplc.com.Back to press releases